Publication
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerAcute Myeloid Leukemiacivic_curation1.00
- drugPonatinibcivic_curation1.00
- drugQuizartinibcivic_curation1.00
- geneFLT3civic_curation1.00
- variantFLT3 D835civic_curation1.00
Curated evidence
Evidence citing this paper (6)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23430109
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FLT3 D8351 | ||||||||
| Ponatinib + QuizartinibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID1036An in-vitro saturation mutagenesis screen of 50 independently derived FLT3-ITD clones was performed to identify mutations that confer resistance to ponatinib. Mutations at 3 AL residues (D835 [n = 31]… (full text at CIViC) PMID 23430109 · Smith et al., 2013 · Open in CIViC | civic |
| FLT3 ITD & D835(V/Y/F/H)1 | ||||||||
| Ponatinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 4 | submitted | EID8894Proliferation of Ba/F3 cells with FLT3 double mutations was studied for the activity of ponatinib. Compared to control cells with native FLT3-ITD mutant (IC50: 3.0nM), cells with double mutants, FLT3-… (full text at CIViC) PMID 23430109 · Smith et al., 2013 · Open in CIViC | civic |
| FLT3 ITD & D839G2 | ||||||||
| Quizartinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID8896Proliferation of Ba/F3 cells with FLT3 double mutations was studied. Compared to control cells with native FLT3-ITD mutant (IC50: 0.13-3.0nM), cells with double mutants (FLT3-ITD/D839G) were sensitive… (full text at CIViC) PMID 23430109 · Smith et al., 2013 · Open in CIViC | civic |
| Ponatinib + SorafenibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 4 | submitted | EID8897Proliferation of Ba/F3 cells with FLT3 double mutations was studied. Compared to control cells with native FLT3-ITD mutant (IC50: 0.13-3.0nM), cells with double mutants (FLT3-ITD/D839G) were sensitive… (full text at CIViC) PMID 23430109 · Smith et al., 2013 · Open in CIViC | civic |
| FLT3 ITD&F691(I/L)1 | ||||||||
| Ponatinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID8893Proliferation of Ba/F3 cells with FLT3 double mutations was studied for the activity of ponatinib. Compared to control cells with native FLT3-ITD mutant (IC50: 3.0nM), cells with double mutants (FLT3-… (full text at CIViC) PMID 23430109 · Smith et al., 2013 · Open in CIViC | civic |
| FLT3 ITD & Y842C1 | ||||||||
| Ponatinib + SorafenibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 4 | submitted | EID8895Proliferation of Ba/F3 cells with FLT3 double mutations was studied for the activity of ponatinib and sorafenib. Compared to control cells with native FLT3-ITD mutant (IC50: 3.0nM), cells with double … (full text at CIViC) PMID 23430109 · Smith et al., 2013 · Open in CIViC | civic |